Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q3 2026 › vs Q3 2025
Lexicon Pharmaceuticals (LXRX) Q3 2026 vs Q3 2025 (year over year)
Lexicon Pharmaceuticals's revenue fell $2.9M (-21%) from $14.2M in Q3 2025 to $11.2M in Q3 2026.
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $11.2M | $14.2M | −$2.9M | -21% |
| Other income, net | $490K | −$582K | $1.1M | — |
| Net loss | $14.0M | $12.8M | $1.2M | +10% |
| Costs & expenses | $25.7M | $27.0M | −$1.2M | -4% |
| Operating costs | $25.7M | $26.4M | −$624K | -2% |
| Cost of revenue | $79K | $10K | $69K | +690% |
| Research & development | $16.2M | $18.8M | −$2.6M | -14% |
| SG&A | $9.5M | $7.6M | $1.9M | +24% |
| Operating cash sources | $14.0M | $12.8M | $1.2M | +10% |
| Depreciation & amortization | $95K | $151K | −$56K | -37% |
| Share-based compensation | $3.4M | $3.4M | −$61K | -2% |
| Working capital & other | $2.4M | −$14.7M | $17.1M | — |
| Cash used in operations | $8.1M | $23.8M | −$15.8M | -66% |
| Net loss absorbed | $14.0M | $12.8M | $1.2M | +10% |
Questions
How much did Lexicon Pharmaceuticals's revenue grow year over year in Q3 2026?
Lexicon Pharmaceuticals's revenue fell $2.9M (-21%) from $14.2M in Q3 2025 to $11.2M in Q3 2026.